A trial of 2 doses of an inhaled glucocorticoid in a fixed-dose triple therapy for chronic obstructive pulmonary disease (COPD) appeared beneficial compared with 1 of 2 dual therapies.
A trial of 2 doses of an inhaled glucocorticoid in a fixed-dose triple therapy for chronic obstructive pulmonary disease (COPD) appeared beneficial compared with 1 of 2 dual therapies, according to a report published in Wednesday’s New England Journal of Medicine.
Triple inhaled therapy for COPD consists of a combined inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA). Triple therapy is recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) for patients who experience recurrent exacerbations despite treatment with either a dual bronchodilator or LABA/ICS combination.
The trial, called ETHOS (Clinical Trials NCT02465567), looked at 4 treatments: a once-daily combination of a single inhaler; fixed-dose triple combination of budesonide, an ICS, with glyopyrrolate, a LAMA; and formoterol fumarate, a LABA, at 2 doses, with budesonide at 320 or 160 μg. The glyopyrrolate and formoterol fumarate doses remained the same across the treatments, at 14.4 and 9.6 μg, respectively.
The metered-dose inhaler, named PT010, was compared with 18 μg of glyopyrrolate plus 9.6 μg of formoterol or 320 μg of budesonide plus 9.6 μg of formoterol. PT010 is sold in Japan and China, but received a Complete Response Letter from the FDA last year, according to AstraZeneca, which sponsored the study.
Over 52 weeks, researchers sought to determine the rate of moderate or severe COPD exacerbations in patients who had at least 1 exacerbation in the previous year. Participants were aged 40 to 80 years; inclusion criteria included being current or former smokers with a history of at least 10 pack-years of cigarette smoking and a forced expiratory volume in 1 second (FEV1) of <65% and a forced vital capacity (FVC) ratio of <0.70..
Of 8509 patients, the annual rates of moderate or severe exacerbations were 1.08 in the budesonide 320-μg group, 1.07 in the budesonide 160-μg group, 1.42 in the glyopyrrolate-formoterol group, and 1.24 in the budesonide-formoterol group.
Using budesonide at 320 μg resulted in lowering exacerbations by 24% compared with glyopyrrolate-formoterol (95% CI, 0.79 -0.83; P <.001) or 13% compared with budesonide-formoterol (95% CI, 0.79-0.95; P <.003).
The rate of reduced exacerbations using budesonide at 160 μg was 25% lower (95% CI, 0.69-0.83; P <.001).
At either dose, the researchers said that the triple therapy of twice-daily budesonide (160/320 μg dose), glycopyrrolate, and formoterol was better at reducing the rate of moderate or severe COPD exacerbations thant glycopyrrolate-formoterol or budesonide-formorterol.
Reference
Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD (ETHOS). N Engl J Med. Published online June 24, 2020. doi:10.1056/NEJMoa1916046
A Pulmonologist on Why You Should Think About Respiratory Health and the Lungs
November 16th 2021On this episode of Managed Care Cast, we speak with MeiLan K. Han, MD, MS, the author of a book released this month called Breathing Lessons: A Doctor’s Guide to Lung Health. Han, a pulmonologist, gives an inside tour of the lungs and how they work, zooms out to examine the drivers of poor respiratory health, and addresses policy changes that are needed to improve lung health.
Listen
COPD Prevalence Did Not Significantly Change Overall From 2011 to 2021, Study Says
November 21st 2023Based on Behavioral Risk Factor Surveillance System data, about 6.4% of US adults in 2011 (14.3 million people) and about 6.5% (14.2 million) had COPD in 2021, showing that COPD prevalence did not significantly change throughout the decade.
Read More
COPD Linked to 28-Day All-Cause Mortality in Patients With Sepsis
November 14th 2023Compared with those without chronic obstructive pulmonary disease (COPD), patients with both sepsis and COPD had higher intensive care unit (ICU) mortality rates, longer ICU stays, and higher in-hospital mortality rates.
Read More
Accelerated Aging Associated With COPD, Impaired Lung Function
November 7th 2023High levels of phenotypic age acceleration (PhenoAgeAccel) were found to have a more significant effect on lung function in patients with chronic obstructive pulmonary disease (COPD), older patients, and White patients.
Read More